Health and Healthcare

Monday's Top Biotech and Medical Stocks

From BioHealth Investor

Biotechnology

NEURO-HITECH INC [NHPI.OB] +17.36%
LEV PHARMACEUTICALS [LEVP.OB] +11.18%
OBAGI MEDICAL [OMPI] +9.16%
GENVEC INC [GNVC] +7.84%
ACHILLION PHARMACEUT [ACHN] +6.71%

Diagnostic Substances

SCOLR PHARMA INC [DDD] +8.00%
LEXICON GENETICS I [LEXG] +6.97%
ASPENBIO PHARMA INC [APNB.OB] +6.12%
ABAXIS INC [ABAX] +5.98%
ICAGEN, INC. [ICGN] +5.32%

Drug Delivery

FLAMEL TECH SA ADR [FLML] +11.22%
INSITE VISION INC [ISV] +7.55%
QUIGLEY CORP THE [QGLY] +3.79%
DELCATH SYSTEMS INC [DCTH] +3.77%
K V PHARMA CL A [KV-A] +2.85%

Drug Manufacturers

PHARMAXIS LTD ADR [PXSL] +9.69%
NITROMED, INC. [NTMD] +7.99%
ADVANCIS PHARMA CP [AVNC] +5.95%
BRADLEY PHARMACTCL [BDY] +5.70%
ATHEROGENICS INC [AGIX] +5.56%

Medical Appliances & Equipment

SYNOVIS LIFE TECH [SYNO] +5.76%
ROCKWELL MED TECHS [RMTI] +4.97%
ALPHA PRO TECH [APT] +4.91%
NORTH AMERN SCI [NASI] +4.85%
SPECTRASCIENCE NEW [SCIE.OB] +4.72%

Medical Instruments & Supplies

NEPHROS INC. [NEP] +22.85%
OCCULOGIX, INC. [OCCX] +21.33%
MICROMED CARDIOVASCU [MMCV.OB] +14.29%
IMMUNOCELLULAR THERA [IMUC.OB] +13.04%
BIOMIMETIC THERAPEUT [BMTI] +9.97%

Medical Laboratories & Research

MEDTOX SCIENTFIC INC [MTOX] +6.38%
RADNET INC [RDNT.OB] +3.68%
ERESEARCHTECHNOLOG [ERES] +2.87%
GENOMIC HEALTH, INC. [GHDX] +2.83%
QUEST DIAGNOSTC [DGX] +1.61%

http://www.biohealthinvestor.com/

Smart Investors Are Quietly Loading Up on These “Dividend Legends” (Sponsored)

If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats. There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside. If you’re tired of feeling one step behind in this market, this free report is a must-read for you.

Click here to download your FREE copy of “2 Dividend Legends to Hold Forever” and start improving your portfolio today.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.